Full
Outline
To investigate the treatment outcome and influencing factors of subclinical tuberculosis (STB) in Guizhou Province, and to provide a reference for further prevention and treatment of STB.
The STB patient information in Guizhou Province from 2021 to 2023 was derived from the National Tuberculosis Management Information System. Baseline characteristics of patients were described, and factors influencing patient treatment outcome were analyzed using χ2 test and multivariable logistic regression, and subgroup analysis was performed.
A total of 4 406 STB patients were registered in Guizhou Province from 2021 to 2023, 190 (4.3%) cases had adverse outcomes, and 4 216 (95.7%) cases were successfully treated. Among them, 2 600 (59.0%) were male, 3 069 (69.7%) were Han, and 2 146 (48.7%) were farmers. 3 532 (80.2%) cases were found after referral and follow-up. Multivariable logistic regression analysis showed that age≥60 years old (OR=2.892, 95% CI: 1.143-7.317), comorbidities (OR=1.632, 95% CI: 1.114-2.392), hematogenous pulmonary tuberculosis (OR=9.618, 95% CI: 1.047-88.317), positive etiology (OR=2.164, 95% CI: 1.539-3.043), and retreatment (OR=5.338, 95% CI: 2.011-14.167) were risk factors for adverse outcomes in STB patients. Primary management (OR=0.124, 95% CI: 0.039-0.392) and use of standard protocols (OR=0.372, 95% CI: 0.262-0.527) were protective factors. The impact of treatment regimen on the treatment outcome of STB patients had interactions in different comorbidities and diagnostic subgroups (interaction P<0.05). Among them, patients with STB without comorbidities (OR=0.22, 95% CI: 0.15-0.31) and patients with secondary STB (OR=0.23, 95% CI: 0.17-0.31) had better treatment effects with the standard regimen.
The majority of subclinical tuberculosis patients in Guizhou Province are male, young and middle-aged, Han nationality, farmers, and secondary pulmonary tuberculosis, and the main source is passive detection. Patients with STB aged≥60 years old, comorbidities, hematogenous pulmonary tuberculosis, positive etiology, retreatment, no primary management, and no use of standard treatment options will increase the risk of adverse outcomes. For the above types of patients, we should focus on the occurrence and development of their clinical treatment outcomes, and take corresponding treatment and management measures to reduce the occurrence of adverse outcomes.
23
13
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
